At its Q3 2026 results briefing, Baicheng said its strategic modular
construction unit has expanded orders and market recognition across biopharma,
food and pharmaceuticals, microelectronics, data centers and lithium‑battery
sectors while building project experience. The unit remains unprofitable because
production capacity has not been ramped up and plant and equipment depreciation,
labour, R&D and market‑development spending continue to weigh on results.